Team:Freiburg/Highlights

From 2013.igem.org

Revision as of 07:34, 3 October 2013 by Stefan.kraemer (Talk | contribs)


HIGHLIGHTS

In the last months we were able to...

  • ...construct a catalytically inactive version of Cas9 and thus generate a new DNA binding protein.
  • ...combine this modified dCas9 with different transcriptional effectors.
  • ...express this system in various mammalian cell lines.
  • ...control mammalian gene expression via our modified CRISPR/Cas system.
  • ...regulate gene expression on light stimulus.
  • ...make our dCas9 accessible to the whole iGEM community by mutating illegal iGEM restriction sites.
  • ...to build an online tool that generates customized manuals for using our toolki.

    In summary we can now offer a universal applicable toolkit for gene regulation.

6 opportunities to customize your experiments

We provide 3 different effectors, 2 methods and 1 effector controller that allows either to effectively repress or activate genes - also on stimulus. Use our custom-tailored Manual Tool to generate individual manuals. Best of all: It's all open source and in iGEM standard!

dCas9 - Heart of our toolkit

We started by mutating the DNA cleavage site in the Cas9 protein and generated a DNA binding protein that is relying on a RNA-DNA interaction. This simple DNA binding protein is the foundation of our project and all effectors used in this toolkit are fused to it.

Activation

The activation domain VP16 is able to activate transcription of genes.

Repression

The fusion of the transcriptional repressor domain KRAB leads to synthetic repression of gene expression.

Chromatin modification (Repression)

Specific chromatin modification was achieved by fusing a histone methyltransferase G9a to dCas9. With this protein we are able to specifically repress endogenous gene expression.

uniBAss - Binding Assay

We developed an ELISA based method. With this method we can quantify the binding efficiency of our proteins. We called this binding assay uniBAss. This is a powerful tool for characterizing the modified dCas9 by assessing its DNA binding capacity.